Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rangering i aksjer #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Aksjekurs
$0.25974701
Sist synkronisert: 2025-01-06
Markedsverdi
$2.04M
Endring (1 dag)
0.74%
Endring (1 år)
0.00%
Land
FR
Handel Acticor Biotech SAS (ALACT)

Kategori

Historikk for aksjesplitt for Acticor Biotech SAS (ALACT)
Aksjen Acticor Biotech SAS (symbol: ALACT) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Sep 15, 2026.
Én ALACT-aksje kjøpt før Sep 15, 2026 tilsvarer i dag 0 ALACT-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH